In a patient with acholic (white) stools, what does a serum alpha‑1 antitrypsin level indicate about possible liver disease or biliary obstruction?

Alpha-1 Antitrypsin Testing in Patients with White (Acholic) Stools

In a patient presenting with acholic stools, serum alpha-1 antitrypsin (AAT) level serves as a screening test to identify alpha-1 antitrypsin deficiency (AATD) as a potential cause of intrahepatic cholestasis, particularly in infants and children, though it must be interpreted alongside phenotype/genotype testing since AAT is an acute phase reactant that can be falsely elevated during illness.

Understanding the Clinical Context

White or acholic stools indicate cholestasis—either from biliary obstruction (extrahepatic) or impaired bile formation/flow (intrahepatic). The diagnostic approach differs significantly based on age:

In Infants and Children

AATD is a common metabolic cause of neonatal cholestasis and should be tested early in the diagnostic workup 1. Neonatal cholestasis (jaundice lasting >2-3 weeks with conjugated bilirubin >25 μmol/L) has a genetic/metabolic cause in 25-30% of cases, with AATD being one of the most frequent 2.

• Critical diagnostic pitfall: Serum AAT levels alone are insufficient because AAT is an acute phase reactant and may be falsely elevated during illness 2
• Correct approach: Check both serum AAT level AND phenotype (MM, ZZ, SZ, MZ, MS) 2
• Homozygous ZZ or compound heterozygous SZ phenotypes can present with severe cholestasis mimicking biliary atresia, including acholic stools and absent biliary excretion on scintigraphy 2

In Adults

AATD testing should be performed after excluding more common causes of cholestasis 3. The diagnostic algorithm proceeds as follows:

1. First: Imaging (ultrasound) to exclude extrahepatic biliary obstruction 1, 4
2. If no obstruction: Test for common intrahepatic causes (antimitochondrial antibodies for primary biliary cholangitis, viral hepatitis) 1
3. Then: Include AATD in the standardized evaluation for other causes of liver disease 5

Interpreting AAT Levels

Normal vs. Abnormal Values

• Normal AAT: Generally >100-150 mg/dL (varies by lab)
• Severe deficiency: <57 mg/dL 6
• Important caveat: Patients with chronic cholestasis often have ELEVATED AAT levels due to inflammation, not decreased levels 7

The Two-Step Diagnostic Approach

Step 1: Serum AAT Level

• If <57 mg/dL → Proceed immediately to phenotype/genotype testing 6
• If normal or elevated → Does NOT exclude AATD in the setting of acute illness or inflammation 2

Step 2: Phenotype/Genotype Testing 8, 3

• Definitive diagnosis requires DNA-based testing (genotyping/sequencing) or protein phenotyping
• Report results using both HGVS nomenclature and Pi typing 8
• Most severe cases: Pi*ZZ genotype (p.E342K mutation)
• Moderate risk: Pi*SZ genotype
• Disease modifiers: Pi*MZ heterozygotes (can develop liver disease with other risk factors) 9, 10

Clinical Implications for Cholestatic Disease

When AATD Causes Cholestasis

In children 2, 11:

• Presents as neonatal cholestatic hepatitis with acholic stools
• May have no biliary excretion on hepatobiliary scintigraphy
• Liver biopsy shows obstructive pattern with PAS-positive, diastase-resistant globules in periportal hepatocytes
• 25% develop cirrhosis within first decade

In adults 9, 10:

• AATD is primarily a disease modifier rather than sole cause
• 94.7% of patients with severe AATD-associated liver disease have concurrent etiologies (MASLD 53.6%, viral hepatitis 16.1%) 6
• Heterozygous Pi*MZ carriers have increased risk with comorbidities

Genetic Testing Recommendations

For cholestatic liver disease without clear cause 3:

• Infants/children: Genetic testing recommended EARLY in workup
• Adults: Test after excluding common causes, especially if unusual features or treatment-resistant

Use next-generation sequencing panels or whole-exome sequencing rather than single-gene Sanger sequencing 3. Consider SERPINA1 gene analysis as part of comprehensive cholestasis panel including:

• ABCB11 (BSEP)
• ABCB4 (MDR3)
• ATP8B1 (FIC1)
• JAG1 (Alagille syndrome)
• Other cholestasis-related genes 2, 3

Practical Management Algorithm

For patients with acholic stools:

1. Confirm cholestasis: Elevated conjugated bilirubin, alkaline phosphatase, GGT 4

2. Exclude obstruction: Ultrasound first-line; MRCP if needed 1, 4

3. If intrahepatic cholestasis confirmed:

   • Neonates/infants: Order AAT level + phenotype simultaneously 2
   • Adults: Include AAT testing in standardized liver disease evaluation 5

4. Interpret results:

   • Low AAT (<57 mg/dL) → Confirm with phenotype/genotype
   • Normal/high AAT → Does not exclude AATD; proceed with phenotype if clinical suspicion remains
   • Consider genetic panel for comprehensive evaluation 3

5. If AATD confirmed: Refer to hepatology for monitoring; no specific treatment exists for liver disease (supportive care, manage complications, consider transplant if end-stage) 11

Key Pitfalls to Avoid

• Never rely on AAT level alone in acute illness—it will be falsely normal or elevated 2
• Don't assume normal AAT excludes AATD in patients with cholestasis and inflammation 7
• Don't forget to test phenotype/genotype even when AAT level is low—this confirms diagnosis and enables family counseling 8
• Don't test only cryptogenic cases—94.7% of AATD liver disease patients have concurrent etiologies 6
• Don't overlook heterozygotes (Pi*MZ) as disease modifiers, especially with metabolic syndrome or viral hepatitis 5, 9, 10